<DOC>
	<DOCNO>NCT02571816</DOCNO>
	<brief_summary>The purpose study compare single-dose pharmacokinetics ASP2215 subject mild moderate hepatic impairment match healthy subject normal hepatic function . This study also assess safety tolerability single-dose ASP2215 subject mild moderate hepatic impairment match control subject .</brief_summary>
	<brief_title>A Study Investigate Effect Hepatic Impairment Pharmacokinetics , Safety Tolerability ASP2215</brief_title>
	<detailed_description>Subjects admit site one day study drug administration ( i.e . Day -1 ) confine site till collection post-dose PK sample ( Day 21 ) . For subject hepatic impairment , subject discharge Day 21 , visit clinical unit Day 24 ( ±1 day ) Day 28 ( ±1 day ) collection post-dose PK sample . End study Visit For Healthy subject take place 1 5 day follow collection last PK sample .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>A prospective subject eligible clinical study follow apply : Subject Body Mass Index ( BMI ) range 18.5 34.0 kg/m2 , inclusive weighs least 50 kg screening . Female subject must nonchildbearing potential ; Postmenopausal ( define least 1 year without menses ) prior screen , Documented surgically sterile ( least 1 month prior screen ) , Female subject must negative pregnancy test screen Day 1 . Female subject must agree breastfeed start screen throughout study period , 45 day final study drug administration . Female subject must donate ovum start screen throughout study period 45 day final study drug administration . Male subject female spouse/partners childbearing potential must use 2 form highly effective birth control ( 1 must barrier method ) start screen continue throughout study period 105 day final study drug administration . Male subject must donate sperm start screen throughout study period 105 day final study drug administration . Subject agree participate another interventional study participate present study , define signing informed consent form completion last study visit . In addition , subject mild moderate hepatic impairment must also meet follow inclusion criterion : Subject must ChildPugh classification Class A ( mild , 5 6 point ) Class B ( moderate , 7 9 point ) liver function impairment screening . A prospective subject exclude participation clinical study follow apply : Female subject pregnant within 6 month prior screen assessment breastfeed within 3 month prior screen . Subject know suspected hypersensitivity ASP2215 , component formulation use . Subject clinically significant history allergic condition ( include drug allergy , asthma , eczema , anaphylactic reaction , exclude untreated , asymptomatic , seasonal allergy prior study drug administration ) . Subject has/had febrile illness symptomatic , viral , bacterial ( include upper respiratory infection ) , fungal ( noncutaneous ) infection within 1 week prior day 1 . Subject long QT interval ( QTc ) baseline Subject history unexplained syncope , cardiac arrest , unexplained cardiac arrhythmia torsades de pointes , structural heart disease , long correct QT interval ( QTc ) syndrome family history long QTc syndrome Subjects hypokalemia hypomagnesemia screening ( define value lower limit normal ) . Subject mean pulse &lt; 40 &gt; 90 bpm ; mean systolic blood pressure ( SBP ) &gt; 160 mmHg ; mean diastolic blood pressure ( DBP ) &gt; 100 mmHg ( measurement take triplicate subject rest supine position 5 minute ; pulse measure automatically ) day 1 . If mean blood pressure exceed limit , 1 additional triplicate take . Subject receive following drugs/products within 2 week prior dose : Strong moderate inhibitor ( e.g. , ketoconazole fluconazole ) inducer ( e.g. , rifampin phenytoin ) cytochrome P450 ( CYP ) 3A4 Inhibitors inducer Pglycoprotein ( Pgp ) Substrates multidrug toxin extrusion ( MATE ) 1 Drugs target serotonin 5hydroxytryptamine receptor 1 ( 5HT1R ) 5 hydroxytryptamine receptor 2B ( 5HT2BR ) Subject history smoking 10 cigarette ( equivalent amount tobacco ) per day within 3 month prior admission clinical unit . Subject history consume 14 unit alcoholic beverage per week within 6 month prior screen history alcoholism drug/chemical/substance abuse within past 2 year prior screen ( Note : 1 unit = 12 ounce beer , 4 ounce wine 1 ounce spirits/hard liquor ) subject test positive alcohol drug abuse screen day 1 ( amphetamine , barbiturate , benzodiazepine , cannabinoids , cocaine , opiates ) . Subject use drug abuse within 3 month prior admission clinical unit . Subject anticipate inability abstain xanthine ( e.g. , caffeine ) , grapefruit , Seville orange ( include marmalade ) , star fruit product contain item 72 hour prior day 1 throughout duration study . Subject significant blood loss , donate 1 unit ( 450 mL ) blood , receive transfusion blood blood product within 60 day donate plasma within 7 day prior day 1 . Subject participate clinical study treat investigational drug within 30 day 5 halflives , whichever longer , prior screen . Subject condition , investigator 's opinion , make subject unsuitable study participation . Subject employee Astellas Group Contract Research Organization . In addition , healthy subject must also NOT meet follow exclusion criterion : Subject use prescribe nonprescribed drug ( include vitamin , oral contraceptive hormone replacement therapy , natural herbal remedy , e.g. , St. John 's Wort ) 2 week prior study drug administration , except occasional use acetaminophen ( 2 g per day ) . Subject clinically significant abnormality follow investigator 's review physical examination , ECG protocol define clinical laboratory test screen day 1 . Subject use inducer metabolism ( e.g. , barbiturate , rifampin ) 3 month prior admission clinical unit . Subject positive serology test hepatitis B surface antigen , hepatitis A virus antibody ( immunoglobulin M ) , hepatitis C virus antibody , hepatitis B core antibody human immunodeficiency virus type 1 2 screening . Subject history evidence clinically significant cardiovascular , gastrointestinal endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal , and/or major disease malignancy , judge investigator . Subject liver chemistry test ( aspartate aminotransferase , alanine aminotransferase , alkaline phosphatase total bilirubin ) upper limit normal day 1 . If test outside reference range , test may repeat . In addition , subject mild moderate hepatic impairment must also NOT meet follow exclusion criterion : Subject clinically significant abnormality , relate current disease state , follow investigator 's review physical examination , ECG protocol define clinical laboratory test screen day 1 . Subject fluctuate rapidly deteriorate hepatic function , indicate strongly vary worsen clinical and/or laboratory sign hepatic impairment within screen period ( e.g. , worsen ascites , infection ascites , fever , active gastrointestinal bleeding ) . Subject change dose regimen medically require medication within last 2 week prestudy examination ( allow co medication patient ) , and/or use unallowed co medication 3 week prior admission clinical unit ( allow : know hepatic enzyme alter agent compound known restrict metabolism ) . Subject presence hepatocellular carcinoma acute liver disease cause infection drug toxicity . Subject severe portal hypertension surgical portosystemic shunt , include Transjugular intrahepatic portosystemic shunt ( TIPSS ) . Subject biliary liver cirrhosis , biliary obstruction cause hepatic impairment relate parenchymal disorder and/or disease liver . Subject sign significant hepatic encephalopathy ( hepatic encephalopathy grade &gt; 2 ) . Subject severe ascites and/or pleural effusion . Subject esophageal/gastric variceal bleed past 6 month prior screen . Subject thrombocyte level 40 × 109 /L and/or hemoglobin 90 g/L . Subject previous liver transplantation . Subject severe moderate renal dysfunction ( estimate glomerular filtration rate [ eGFR ] 60 mL/min/1.73m2 ) estimate via follow Modification Diet Renal Disease ( MDRD ) equation : eGFR ( mL/min/1.73 m2 ) = 175 × ( SCr [ mg/dL ] ) 1.154 × ( Age ) 0.203 × ( 0.742 female ) × ( 1.212 black )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>ASP2215</keyword>
	<keyword>Healthy</keyword>
	<keyword>Hepatic Impairment</keyword>
	<keyword>Mild Hepatic Impairment</keyword>
	<keyword>Moderate Hepatic Impairment</keyword>
</DOC>